Thioredoxin domain containing 5 (TXNDC5) as a marker of response in multiple myeloma – validation studies of proteomic profiling

MLA

Malathi Kandarpa, et al. “Thioredoxin Domain Containing 5 (TXNDC5) as a Marker of Response in Multiple Myeloma – Validation Studies of Proteomic Profiling.” Acta Haematologica Polonica, vol. 44, July 2013, p. 38. EBSCOhost, https://doi.org/10.1016/j.achaem.2013.07.294.

APA

Malathi Kandarpa, Andrzej Jakubowiak, Dattatreya Mellacheruvu, Dominik Dytfeld, Arun Sreekumar, Jagoda Jasielec, Mieczysław Komarnicki, Stephanie J Kraftson, Alexey I. Nesvizhskii, Paul G. Richardson, Mattina Alonge, Shaun Rosebeck, S. Subramani, Lambert Ngoka, & J.R. Strahler. (2013). Thioredoxin domain containing 5 (TXNDC5) as a marker of response in multiple myeloma – validation studies of proteomic profiling. Acta Haematologica Polonica, 44, 38. https://doi.org/10.1016/j.achaem.2013.07.294

Chicago

Malathi Kandarpa, Andrzej Jakubowiak, Dattatreya Mellacheruvu, Dominik Dytfeld, Arun Sreekumar, Jagoda Jasielec, Mieczysław Komarnicki, et al. 2013. “Thioredoxin Domain Containing 5 (TXNDC5) as a Marker of Response in Multiple Myeloma – Validation Studies of Proteomic Profiling.” Acta Haematologica Polonica 44 (July): 38. doi:10.1016/j.achaem.2013.07.294.